Product Information
LUBIPROSTONE 24 MCG CAPSULE is a generic product labeled by Par Health USA, LLC, priced at $0.6507 per EA under NDC 00254302902. Its NADAC has been published 285 times since Apr 21, 2021.
FDA first approved this application on Jan 31, 2006. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
24 ug/1
Manufacturer
Par Health USA, LLCNDC
00254302902
Classification
Generic
Dosage Form
CAPSULE, GELATIN COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LUBIPROSTONEApproval Type
Authorized Generic (NDA)
FDA Application
NDA021908FDA Approved
1/31/2006
TE Code
AB
On Market Since
1/1/2021
Pharmacological Classes
Price Statistics
The NADAC for LUBIPROSTONE 24 MCG CAPSULE has been published 285 times since Apr 21, 2021, and over the history we have for it it has declined 86.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6507 per EA |
|---|---|
| All-time high | $4.7127 (May 12, 2021) |
| All-time low | $0.5868 (Nov 20, 2024) |
| 52-week high | $0.8250 |
| 52-week low | $0.6239 |
| Median price | $1.2408 |
| Average price | $2.2622 |
| Largest weekly change | +44.9% (Nov 22, 2023) |
| Weeks tracked | 285 |
| Tracking since | Apr 21, 2021 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Par Health USA, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Lubiprostone market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Chloride Channel Activator class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LUBIPROSTONE 24 MCG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for LUBIPROSTONE 24 MCG CAPSULE, manufactured by Par Health USA, LLC, is $0.6507 per EA (NDC 00254302902), effective Sep 30, 2026.
How has the price of LUBIPROSTONE 24 MCG CAPSULE changed over time?
Over the history we have for it, the NADAC for LUBIPROSTONE 24 MCG CAPSULE has declined 86.2%. It has been tracked across 285 weekly CMS publications since Apr 21, 2021.
What are the highest and lowest recorded NADAC prices for LUBIPROSTONE 24 MCG CAPSULE?
Since Apr 21, 2021, the NADAC for LUBIPROSTONE 24 MCG CAPSULE has ranged from a low of $0.5868 (Nov 20, 2024) to a high of $4.7127 (May 12, 2021), with a median of $1.2408 per EA.
Are there cheaper alternatives to LUBIPROSTONE 24 MCG CAPSULE?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LUBIPROSTONE 24 MCG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures LUBIPROSTONE 24 MCG CAPSULE?
LUBIPROSTONE 24 MCG CAPSULE (NDC 00254302902) is labeled by Par Health USA, LLC, and CMS classifies it as a generic product.